Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Compumedics Limited ( (AU:CMP) ) has shared an update.
Compumedics reported record first-half fiscal 2026 sales orders of $34.9 million and revenue of $31.0 million, driven by stronger demand for its core sleep and neuro platforms and improved conversion of orders to shipments. The company’s growing software-as-a-service and annuity streams lifted recurring revenue, with SaaS revenue up 56% to $4.6 million, supporting a profitable swing to a $0.3 million net profit and EBITDA of $3.1 million.
Momentum in the magnetoencephalography (MEG) business, including $6.5 million of invoicing and a new $4.9 million system order, underpinned earnings quality and contributed to cash from operations of $1.8 million, versus an outflow a year earlier. Management reaffirmed full-year guidance for about $70 million in revenue and up to $9 million in EBITDA, signalling confidence in execution as cost discipline and a $2 million per annum efficiency program aim to further enhance margins and resilience of the revenue mix.
The most recent analyst rating on (AU:CMP) stock is a Hold with a A$0.35 price target. To see the full list of analyst forecasts on Compumedics Limited stock, see the AU:CMP Stock Forecast page.
More about Compumedics Limited
Compumedics Limited is an Australian medical technology company focused on sleep and neurology diagnostics, including capital equipment and connected software platforms. The group is expanding its software-as-a-service offerings through Somfit and Nexus 360, targeting more recurring, cloud-based revenues alongside traditional device sales in key markets such as Asia, Europe, Australia and New Zealand.
Average Trading Volume: 79,706
Technical Sentiment Signal: Buy
Current Market Cap: A$69.92M
See more data about CMP stock on TipRanks’ Stock Analysis page.